CAS NO: | 953778-58-0 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 380.41 |
---|---|
Formula | C20H23F3N2O2 |
CAS No. | 953778-58-0 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 10 mM |
Water: <1 mg/mL | |
Ethanol: <1 mg/mL | |
Chemical Name | (R)-2-(4-isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
Synonyms | MK-8998; MK8998; MK 8998 |
In Vitro | In vitro activity: MK-8998 is a potent and selective antagonist of the T-type calcium channel that is being investigated as a potential new therapy for the treatment of schizophrenia. Because MK-8998 does not block D2, 5HT2a, muscarinic, or histaminic receptors, it has the potential for a substantially improved side effect profile compared with currently available atypical antipsychotics. Kinase Assay:MK-8998 is a potent and selective antagonist of the T-type calcium channel. Cell Assay: |
---|---|
In Vivo | MK-8998 is not effective in treating acutely psychotic inpatients with schizophrenia. There are no significant differences between either MK-8998 or olanzapine versus placebo at any time point. MK-8998 and olanzapine are generally well tolerated but are associated with a higher percentage of adverse events compared with placebo |
Animal model | |
Formulation & Dosage | |
References | Hum Psychopharmacol. 2013 Mar;28(2):124-33. |